Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab
-
Published:2023-11
Issue:
Volume:
Page:
-
ISSN:2468-6530
-
Container-title:Ophthalmology Retina
-
language:en
-
Short-container-title:Ophthalmology Retina
Author:
Raimondi RaffaeleORCID,
Falfeli TinaORCID,
Bogdanova-Bennet Anna,
Varma Deepali,
Habib Maged,
Kotagiri Ajay,
Steel David H.ORCID,
Grinton MichaelORCID
Reference20 articles.
1. Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013;Quartilho;Eye (Lond),2016
2. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP);Rofagha;Ophthalmology,2013
3. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study;Brown;Ophthalmology,2009
4. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration;Heier;Ophthalmology,2012
5. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials;Heier;Lancet,2022
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献